drugset / Trial / NCT03882359

An Ascending Dose Comparison of MVT-100 to Definity in Healthy Volunteers

NCT03882359

RandomizedParallel-groupSingle-blindDiagnostic

Summary

Definity (perflutren lipid microspheres, Lantheus Medical Imaging) is an ultrasound contrast indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border. MVT-100 (the investigational pharmaceutical) is similar to Definity, with the exception of the removal of one lipid in the lipid blend and substitution of another lipid. This study is intended to evaluate the safety and efficacy of MVT-100 using a single ascending dose design in healthy volunteers. Patients are randomized to receive either MVT-100 or Definity and undergo echocardiograms after receiving either MVT-100 or Definity via bolus or IV infusion administration. The primary endpoints evaluated are safety and endocardial border delineation.

Timeline

Start
2019-04-25
Primary completion
2024-09-30
Completion
2025-05-06

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Definity Diagnostic / imaging agent 0.1 ml Intravenous
Comparator Definity Diagnostic / imaging agent 0.2 ml Intravenous
Comparator Definity Diagnostic / imaging agent 0.3 ml Intravenous
Comparator Definity Diagnostic / imaging agent 1 unknown Intravenous
Subject MVT-100 Unknown 0.1 ml Intravenous
Subject MVT-100 Unknown 0.2 ml Intravenous
Subject MVT-100 Unknown 0.3 ml Intravenous
Subject MVT-100 Unknown 1 unknown Intravenous

Indications